Buradasınız

Anasayfa » Content

DENEYSEL DİYABET MODELİNDE NEFROPATİNİN ERKEN DÖNEMİNDE SPESİFİK ANJİOTENSİNII RESEPTÖR ANTAGONİSTİ LOSARTANIN ETKİLERİ

THE EFFECT OF SPECIFIC ANGIOTENSIN RECEPTOR ANTAGONIST LOSARTAN ON DIABETIC NEPHROPATHY IN DIABETIC RAT MODEL

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1997

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Angiotensin converting enzyme inhibitors prevent the development of diabetic nephropathy by both blocking the renin-angiotensin system and increasing bradykinin levels through inhibition of the kininase II enzyme. Angiotensin receptor antagonists have specific effect on the renin angiotensin system and do not inhibit kininase II enzyme activity. In this study we aimed to investigate the effect of losartan on diabetic nephropathy and to compare it with captopril therapy. Fifty four female Wistar rats, 10-14 weeks old, enrolled in the study. Rats were made diabetic by intraperitoneal injection of streptosotocin in pH 4.5 sodium citrate buffer and did not receive any antidiabetic treatment. Following the first month of injection rats were separated into three groups: The first group received losartan 10 mg/kg via an orogastric catheter, the second group received captopril 50 mg/l in drinking water, and the third one served as the diabetic control group. Twenty four hour urine samples were collected before and after the first mouth of treatment in separate metabolic cages in order to measure urinary albumin, heparan sulphate, and creatinine excretions. Serum glucose and creatinine levels were determined from the blood samples collected via the intracardiac route. The non-diabetic controlgroup consisted of six healthy and age matched female rats. Urinary albumin excretion rates were similar at the first month, before the beginning of treatment, among the losartan, captopril, and diabetic control groups (952±689 mg/day, 970±547mg/day, 910±514 mg/day, respectively). Following the second month urinary albumin excretion rate significantly increased in the control group (1724±945 mg/day, p<0.005). The urinary albumin excretion rates were comparable between losartan and captopril groups, both being significantly lower than that of the control group (778±221 mg/day and 719±341 mg/day, respectively , p<0.05). Urinary heparan sulphate excretion, creatinine clearance and serum creatinine levels were not different among the three groups. In conclusion, losartan prevented the progressive increase in urinary albumin excretion rate in diabetic rats. The effects of losartan and captopril treatment were found to be similar.
Abstract (Original Language): 
Diyabetik nefropati gelişim sürecinde, anjiotensin dönüştürücü enzim inhibitörlerinin olumlu etkileri hem renin-anjiotensin sisteminin bloke edilmesi, hem de kininaz II enzimi inhibisyonu ile bradikinin düzeylerinin artması yoluyla oluşmaktadır. Kininaz II enzim aktivitesi üzerinde belirgin etkisi olmayan, anjiotensin II tip I reseptör antagonistlerinin diyabetik nefropati sürecindeki etkileri tam anlamıyla ortaya konulamamıştır. Bu çalışmanın amacı, losartanın diyabetik nefropati sürecindeki etkilerini araştırmak ve kaptopril ile karşılaştırmaktır. Çalışmaya 54 adet 10-14 haftalık dişi Wistar rat alındı. Raflarda pH 4.5 sodyum sürat tamponu içinde streptozotosin 65mg/kg periton içine verilerek diyabet oluşturuldu ve antidiyabetik tedavi uygulanmadı. Enjeksiyondan bir ay sonra ratlar üç gruba ayrıldı. Birinci gruba 10mg/kg losartan gavaj ile, ikinci gruba 50 mg/l kaptopril içme suyu içerisinde verildi. Diğer ratlar diyabetik kontrol grubu olarak izlendi .Tedavi başlangıcında ve bir aylık tedavi sonunda ratlar metabolik kafeslere alınarak, 24 saatlik idrar toplandı, bu örneklerde albumin, heparan sülfat ve kreatinin değerleri ölçüldü. İntrakardiyakyolla alınan kan örneklerinde, serum glukoz ve kreatinin düzeyleri çalışıldı. Altı adet sağlıklı ve aynı yaşta rat ile sağlıklı kontrol grubu oluşturuldu. Birinci ay sonunda, tedavi başlamadan önce, losartan, kaptopril ve diyabetik kontrol gruplarında idrarda albumin itrahı benzer oranlardaydı (sırası ile 952±689 mg/gün, 970±547 mg/gün, 910±514 mg/gün). Kontrol grubunda ikinci ay sonunda albumin itrahı belirgin olarak artarken (1724±945mg/gün, p<0.005), losartan ve kaptopril gruplarında hafif bir azalma gözlendi. Bu değerler kendi aralarında farksız, kontrol grubuna göre anlamlı ölçüde düşük olarak bulundu (sırası ile 778±221 mg/gün ve 719±341 mg/gün , p<0.05). İdrarda heparan sülfat itrahı, kreatinin klirensi ve serum kreatinin düzeyleri açısından anlamlı farklılık gözlenmedi. Sonuç olarak diyabetik rotlarda losartan tedavisi ile albümin itrahındaki artış durdurulabilmektedir. Diyabetik ratlarda losartan ve kaptopril tedavisinin etkileri bakılan parametreler açısından birbirleri ile eşdeğer bulunmuştur.
FULL TEXT (PDF): 
PDF icon pdf_tndt_179.pdf

REFERENCES

References: 

1. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T: Diabetic nephropathy in type I (insulin-dependent) diabetes: An epidemiologic study. Diabetologia 1983; 25:496-501.
2. Krolewski AS, Warram JA, Christlieb AR, Busick EJ, Kahn JR: The changing natural history of nephropathy in type I diabetes. Am J Med 1985; 78:785-79.
3. Ballard DJ, Humprey LL, Melton LJ, Frohnert PP, Chu
CP, O'Fallon WM, Palumbo PJ: Epidemiology of persistant proteinuria in type II diabetes mellitus. Diabetes
1988; 37:405-412.
4. Viberti G, Wiseman MJ, Pinto JR, Messent J: Diabetic nephropathy. In:Kahn CR, Weir GC eds. Joslin's Diabetes
Mellitus. Pennsylvania: Lea&Febiger 1994; 691-737.
5. Mahnensmith RL: Diabetic nephropathy: A comprehensive approach. Hospital Practice 1993; 28:
129-148.
6. Dunffe TP: The changing management of diabetic nephropathy. Hospital Practice 1995; 30:45-55.
7. Bennett PH, Haffner S, Kasiske BL et al. Striker
GE:Screening and management of microalbuminuria in patients with diabetes mellitus. Am J Kid Dis 1995; 25:107-112.
8. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF:
Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann
IntMed 1993; 118:129-13.
9. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with
microalbuminuria. Br Med J 1991; 303:81-87.
10. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M:
Long term stabilising effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann
IntMed 1993; 118:577-581.
11. Lebovitz HE, Wiegmann TB, Cnaan A. et al. Renal protective effects of enalapril in hypertensive NIDDM: Role ofbaseline albuminuria. Kidney Int 1994; 45:S150-
S155.
12. Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with
diabetic nephropathy Br Med J 1986; 293:471-474.
13. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M: Renal protective effect of enalapril in diabetic
nephropathy. Br Med J 1992; 304:339-343.
14. Tuck ML, Samphi MP, Levin L: Hyporeninemic hypoaldosteronism in diabetes mellitus: studies of the autonomic nervous system's control of renin release.
Diabetes 1979; 28:237-24.
15. Toto RD, Mitchell HC, Lee II C, Milam C, Pettinger WA Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991; 115:513-519.
16. Hanssens M, Keirse MJNC, Vankelcom F, Van Assche FA: Fetal and neonatal effects of treatment with angiotensin converting enzyme inhibitors in pregnancy.
Obstet Gynecol 1991; 78:128-135.
17. Simon SR, Black HR, Moser M, Berland WE: Cough and
ACE inhibitors. Arc Int Med 1992; 152:1698-1700.
18. Ramsay LE, Yeo WW: ACE inhibitors, angiotensin II and cough. J Human Hypertensl995; 9.S51-S54.
19. Just PM: The positive association of cough with angiotensin converting enzyme inhibitors
Pharmacotheraphy 1989; 9:82-87.
20. Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.
Ann Intern Med 1992; 117:234-242.
21. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WHW: Clinical profile of angioedema associated with angiotensin converting enzyme
inhibition. JAMA 1988; 260:967-970.
22. Schulman G, Hakim R, Arias R, Silverberg M, Kaplan
110
AP, Arbeit L: Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J Am Soc Nephrol 1993; 3:1563-1569.
23. Wong PC, Price WA, Chiu AT. et al. Nonpeptide angiotensin II receptor antogonists: Studies with EXP9270 and Dup753. Hypertension 1990; 15:823-834.
24. Brunner HR, Nussberger J, Waeber B: Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system. J Hypertens
1993; 11:S53-S58.
25. Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J: Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clinical
Therapeutics 1996; 18:608-625.
26. Sweet CS, Nelson EB: How well have animal studies with losartan predicted responses in humans? J Hypertens
1993; 11:S63-S67.
27. Reddi AS: Prevention of albuminuria by captopril in diabetic rats. Gen Pharmacol 1991; 22:323-328.
28. Jong JGN, Wevera RA, Laarakkers C, Poorthula BJHM:
Dimethymethylen blue based spectrophotometry of glycoaminoglycans in untreated urine: A rapid screening procedure for mucopolysaccharidoses. Clin Chem. 1989;
35:1472-1477.
29. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE: Effects of angiotensin II antagonist in hypertensive patients with renal disease. J Hypertension
1994; 12:S37-S42.
30. Anderson S, Rennke HG, Garcia DL, Brenner B: Short and long term effects of antihypertensive therapy in the
diabetic rat. Kidney Int 1989; 36:526-536.
31. Remuzzi A, Perico N, Amuchastegui CJ, Malanchini B: Short and long term effects of angiotensin II reseptör blockade in rats with experimental diabetes J Am Soc
Nephrol 1993; 4:40-49.
32. Kohzuki M, Yassujima M, Kanazawa M. et al. Antihypertensive and renal protective effects of losartan in the streptozotocin diabetic rats. J Hypertens 1995; 13:97-103.
33. Gandhi SK, Ryder DH, Brown NJ: Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 1996; 28:961-966.
34. Cohen MP, Klepser H, Wu VY: Undersulfation of
glomerular basement membrane heparan sulfate in experimental diabetes and lack of correction with aldose
reductase inhibition. Diabetes 1988; 37:1324-1327.
35. Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M: Glomerular size and charge selectivity in insulin dependent diabetes mellitus. Kidney Int 1988; 33:100¬106.
36. Reddi AS: Glomerular and urinary glycosaminoglycans in diabetic rats. Clinica Chimica Acta 1990; 189:211¬220.
37. Baggio B, Briani G, Cicerello E. et al. Urinary glycosaminoglycans, sialic acid and lysosomal enzymes increase in nonalbuminuric diabetic patients. Nephron
1986;43:187-190.
38. Baggio B, Briani G, Cicerello E, Gambaro G, Borsatti A, Crepaldi G: Urinary glycosaminoglycan excretion and microalbuminuria in diabetes. JAMA 1986; 255:3250¬3251.
39. Deckert T, Feldt-Rasmussen B, Mathiesen E, Baker L: Pathogenesis of incipient nephropathy: a hypathisis.
Diabetic Nephropathy 1985; 2:83-88.
40. Rasch R, Mogensen CE: Urinary excretion of albumin and total protein in normal and streptosotocin diabetic
rats. Acta Endocrinol 1980; 95:376-381.
41. Gambaro G, Venturini AP, Barbanti M, Nasuato MA,
Bsertaglia G, Baggio B: Urinary excretion of glycoaminoglycans and albumin in experimental
diabetes. Contrib Nephrol 1993; 101:109-113.
42. Reddi AS, Ramamurthi R, Miller M, Dhuper S, Lasker
N: Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats.
Biochem Med Metab Biol 1991; 45:119-131.
43. Reddi AS: Prevention of albuminuria by captopril in diabetic rats. Gen Pharmacol 1991; 22:323-328.

Thank you for copying data from http://www.arastirmax.com